← The Library Research Portal →

Clinical Trials in Longevity: The New Frontier of Aging Research

Published February 2026 · 22 min read

For decades, aging research remained confined to laboratories, studying model organisms like yeast, worms, and mice. The translation to human clinical trials faced seemingly insurmountable obstacles: aging wasn't recognized as a disease by regulatory agencies, the timescales required were prohibitive, and the endpoints were unclear. How do you measure success when studying something as complex and gradual as human aging?

But the landscape has transformed dramatically in recent years. A new generation of clinical trials is testing whether interventions shown to extend lifespan and healthspan in animals can do the same in humans. From repurposed generic drugs to cutting-edge cellular reprogramming, these trials represent humanity's first serious attempt to treat aging itself rather than merely its symptoms.

This article explores the current state of longevity clinical trials—their designs, challenges, results, and what they reveal about the future of aging research.

The Challenge of Studying Aging

The fundamental obstacle to aging research has always been regulatory. The U.S. Food and Drug Administration (FDA) does not recognize aging as an indication for drug approval. Without aging as a legitimate therapeutic target, pharmaceutical companies have little incentive to invest in trials that might take decades to show mortality benefits.

This creates a paradox: the diseases we can treat—cancer, cardiovascular disease, dementia, diabetes—are largely consequences of aging. Yet we cannot directly target the underlying process that gives rise to all of them. As researchers have noted, treating aging could prevent or delay multiple age-related diseases simultaneously, a far more efficient approach than addressing each condition separately.

The solution has been to use composite endpoints—measuring not lifespan directly, but clusters of age-related outcomes: cardiovascular events, cancer incidence, cognitive decline, and all-cause mortality. This approach allows researchers to demonstrate that an intervention delays the onset of multiple aging-related conditions without claiming to treat "aging" per se.

Another major challenge is the timeline. Traditional phase 3 clinical trials for longevity interventions would need to follow participants for decades to measure lifespan extension. This is both prohibitively expensive and scientifically inefficient. The field has responded by focusing on surrogate endpoints—biomarkers that correlate with aging but can be measured in months or years rather than decades. These include biological age clocks, inflammatory markers, mitochondrial function, and measures of physical performance.

Finally, there's the question of whom to study. Should trials focus on young, healthy adults to maximize preventive benefits? Middle-aged individuals showing early signs of decline? Or elderly populations where effects might be more measurable but intervention comes later? Each approach has merits and tradeoffs, and different trials have made different choices.

TAME: The Trial That Could Change Everything

The Targeting Aging with Metformin (TAME) trial represents a watershed moment in longevity research—not necessarily because of what it will discover about metformin, but because of what it could accomplish for the field itself.

Designed by a consortium of geroscientists led by Dr. Nir Barzilai at the Albert Einstein College of Medicine, TAME aims to enroll 3,000 participants aged 65-79 across approximately 14 U.S. centers. The trial's primary endpoint is time to development of a composite outcome including cardiovascular disease, cancer, cognitive decline, and death. If successful, TAME could establish aging as a therapeutic indication, creating a regulatory pathway for future longevity interventions.

Why Metformin?

Metformin, a generic diabetes drug used by hundreds of millions worldwide, has an excellent safety profile and substantial observational evidence suggesting longevity benefits. Epidemiological studies have found that diabetic patients on metformin sometimes outlive non-diabetic controls, and the drug has shown lifespan-extending effects in multiple model organisms.

The proposed mechanisms are multiple: metformin activates AMPK (a cellular energy sensor that promotes metabolic health), reduces inflammation, improves insulin sensitivity, and may enhance cellular stress resistance. Recent research has also shown that metformin can decelerate biomarkers measured by aging clocks, suggesting effects on fundamental aging processes.

Current Status and Challenges

Despite a decade of planning and FDA approval of the trial design, TAME has faced persistent funding challenges. As reported in 2024, the trial remains only partially funded. The estimated cost ranges from $45 to $70 million—a modest sum by pharmaceutical industry standards, but difficult to raise for a generic drug with no profit potential for sponsors.

According to recent updates from Dr. Barzilai, the trial is now being handled within ARPA-H (Advanced Research Projects Agency for Health), a new U.S. government agency focused on high-risk, high-reward biomedical research. This could finally provide the funding needed to launch the study.

Interestingly, the pharmaceutical company Eli Lilly has announced plans to conduct a TAME-like study using their GLP-1 receptor agonist—a sign that the trial design itself has value beyond metformin. As Barzilai noted, "The most important thing about TAME is that it's a template for the pharmaceutical industry."

The Skeptical View

Not everyone is convinced metformin will deliver. A 2025 review noted emerging uncertainty about metformin's anti-aging potential, pointing out that the drug "has generally not demonstrated its anticipated benefits in most clinical trials in nondiabetic populations." This highlights a crucial lesson: observational data in disease populations doesn't always translate to interventional benefits in healthy aging.

Whether TAME succeeds or fails on its primary endpoints, its regulatory precedent could be transformative. It demonstrates to the FDA that aging-related composite endpoints are feasible, opening the door for trials of other longevity interventions.

PEARL: Crowdfunding Rapamycin Research

While TAME has struggled with institutional funding, the Participatory Evaluation (of) Aging (With) Rapamycin for Longevity (PEARL) trial took a different approach: crowdfunding. Organized through AgelessRx and funded by citizen-scientists willing to pay to participate, PEARL became the largest human trial of rapamycin for aging to date.

Study Design

PEARL was a 48-week decentralized, double-blind, randomized, placebo-controlled trial following 114 healthy individuals aged 50-85. Participants received either placebo or 5-10mg of rapamycin once weekly (equivalent to approximately 1.4-2.9mg of generic rapamycin). The trial design focused on safety metrics and healthspan indicators rather than lifespan extension.

Key Findings

Results published in 2025 showed that low-dose, intermittent rapamycin was relatively safe over the study period. Particular attention was paid to immune function—rapamycin's immunosuppressive effects at high doses are well-documented. However, reports of cold/flu-like illness and recovery time were similar across all groups, suggesting the low doses used didn't significantly compromise immune competence.

The healthspan findings were more modest than hoped. Women taking 10mg showed improvements in lean tissue mass and self-reported pain. Those on 5mg reported better emotional well-being and general health. But as critics noted, the trial "relied largely on self-reporting and did not provide direct evidence that rapamycin use extends the lives of humans, and most of its effects on long-term health were limited."

What PEARL Revealed

Despite mixed results, PEARL demonstrated several important points. First, decentralized trials using direct-to-consumer models can successfully recruit and retain participants for aging research. Second, low-dose rapamycin appears safe enough to justify larger, longer studies. Third, as analysts pointed out, "broader measures of immunocompetence including T cell repertoire diversity, innate immune activity, and real-world infection resistance remain underexplored in human rapamycin trials."

The future of rapamycin research may lie in combination approaches, personalized dosing based on biomarkers, or targeted delivery to specific tissues. PEARL was a proof-of-concept for both the drug and the trial model—further refinement of both is needed.

Dog Aging Project: Man's Best Friend as Research Partner

One of the most innovative approaches to longevity research involves our canine companions. The Dog Aging Project is a massive longitudinal study following tens of thousands of companion dogs to understand aging across breeds, lifestyles, and environmental factors. Within this broader effort, the Test of Rapamycin In Aging Dogs (TRIAD) trial is testing whether rapamycin can extend canine lifespan and healthspan.

Why Dogs?

Dogs offer several advantages as aging research subjects. They age roughly seven times faster than humans, allowing lifespan studies to be completed in years rather than decades. They share our environment, experiencing similar exposures to pollution, processed foods, and stress. They develop many of the same age-related diseases we do: cancer, heart disease, cognitive decline, arthritis. And perhaps most importantly, companion dogs receive excellent veterinary care and monitoring, creating high-quality longitudinal data.

The Dog Aging Project represents citizen science at its best—dog owners voluntarily providing health data, completing surveys, and in some cases having their pets enrolled in interventional trials. This creates a massive dataset correlating genetics, environment, interventions, and outcomes across thousands of dogs.

TRIAD Trial Design

The TRIAD trial is a parallel-group, double-masked, randomized, placebo-controlled study testing oral rapamycin in healthy middle-aged dogs. The trial aims to enroll 580 medium-to-large breed dogs at least 7 years old, who receive either rapamycin or placebo for one year, followed by a two-year observation period.

Primary objectives include determining whether rapamycin increases lifespan and improves healthspan metrics: physical function, cardiovascular health, and neurocognitive status. As of early 2025, over 180 dogs have been enrolled, with some already completing the three-year protocol.

Recent Developments

In January 2025, the Dog Aging Project received a five-year, $7 million grant from the National Institute on Aging—a significant endorsement of the approach and a rescue after previous funding challenges. Researchers hope to complete enrollment by end of 2025 and initiate medication by spring 2026.

Early pilot data from a smaller study showed that rapamycin improved cardiac function in middle-aged dogs over 10 weeks. Whether this translates to extended lifespan remains to be seen, but TRIAD is positioned to provide the answer within the next few years—data that would take decades to generate in humans.

CALERIE: The Gold Standard for Caloric Restriction

If there's one intervention with the strongest evidence for slowing aging across species, it's caloric restriction (CR)—reducing calorie intake without malnutrition. The Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy (CALERIE) trials represent the most rigorous examination of CR in humans to date.

Study Design

CALERIE Phase 2 was a multicenter, randomized controlled trial enrolling young and middle-aged adults (21-50 years old) with healthy BMI (22.0-27.9 kg/m²). Participants were assigned 2:1 to either a 25% calorie restriction diet or an ad libitum control group, followed for two years.

This was not a weight loss study—participants were already non-obese. The question was whether CR could slow biological aging in already-healthy individuals, mimicking the profound effects seen in laboratory animals.

Adherence and Outcomes

Achieving 25% caloric restriction in free-living humans proved challenging. Participants in the CR group achieved a mean reduction of 11.9% in calorie intake (from 2467 to 2170 kcal), sustained over two years—a significant accomplishment, though short of the target.

This "moderate" caloric restriction still produced substantial benefits. CR participants lost a mean of 7.5 kg (mostly fat mass) while controls gained 0.1 kg. More importantly, CR caused persistent reductions in cardiovascular risk factors: lower LDL cholesterol, better total:HDL cholesterol ratios, and reduced blood pressure.

Metabolic Adaptations

CALERIE revealed how CR achieves its effects. Participants showed reductions in mass-specific resting metabolic rate and total energy expenditure, accompanied by decreases in thyroid hormone (T3), leptin, and oxidative stress markers. These changes mirror those seen in CR animals and suggest the activation of conserved longevity pathways.

Biological Age Effects

Perhaps most significantly, CALERIE slowed the pace of aging as measured by DNA methylation clocks, particularly the DunedinPACE algorithm designed to capture the rate of biological aging. The intervention also affected telomere length, a marker of cellular aging, though effects varied by individual.

Importantly, CR improved diet quality without compromising nutritional adequacy—participants ate more nutrient-dense foods to meet requirements within restricted calories. Quality of life, physical function, and immune health all improved.

Implications

CALERIE demonstrated that caloric restriction can slow biological aging in humans without obesity, at least over a 2-year timeframe. The challenge is sustainability—can individuals maintain even modest caloric restriction for decades to achieve meaningful lifespan extension? This has spurred interest in CR mimetics: drugs or interventions that activate the same pathways without requiring dietary restriction. Candidates include metformin, rapamycin, and NAD+ precursors.

TRIIM: Reversing the Epigenetic Clock

In 2019, a small trial produced results that seemed almost too good to be true: participants showed evidence of epigenetic age reversal—their biological age, as measured by DNA methylation patterns, appeared to decrease over the course of treatment.

The Original TRIIM Trial

The Thymus Regeneration, Immunorestoration, and Insulin Mitigation (TRIIM) trial, led by Dr. Greg Fahy, enrolled nine healthy men aged 51-65. The intervention combined recombinant human growth hormone (rhGH) with DHEA (dehydroepiandrosterone) and metformin over one year.

The primary goal was thymus regeneration. The thymus, which produces T cells critical for immune function, atrophies with age, becoming largely replaced by fat tissue. The trial showed regeneration of functional thymic tissue, improved immune markers, and reduced risk indices for cardiovascular disease and diabetes.

But the headline finding was epigenetic: participants showed a mean reduction in biological age of approximately 1.5 years after one year of treatment, as measured by multiple DNA methylation clocks. This marked the first demonstration that regression of multiple aging biomarkers was possible in humans.

Mechanism and Controversy

The intervention's mechanism likely involves multiple components. Growth hormone stimulates cellular regeneration but can increase diabetes risk and cancer susceptibility—hence the inclusion of metformin. DHEA may support immune function and hormonal balance. The combination appears to have reversed some aspects of immune aging while avoiding major adverse effects.

Skeptics noted the small sample size (only nine participants, no placebo control) and questioned whether changes in epigenetic clocks represent true biological age reversal or simply reflect the intervention's metabolic effects. The trial's design as an "exploratory" pilot meant it raised more questions than it answered.

TRIIM-X and Beyond

Dr. Fahy and collaborators have continued this work through TRIIM-X, an expanded trial evaluating personalized treatment regimens for thymus regeneration. 2024 updates indicate the trial is ongoing, measuring biomarkers of epigenetic aging, immunosenescence, and established clinical measures for age-related diseases.

The company Intervene Immune has been established to commercialize the approach. Whether TRIIM represents a genuine aging reversal protocol or a specialized intervention for immune restoration remains to be determined by larger, controlled trials. But it demonstrated proof-of-concept: with the right combination of interventions, some aging biomarkers can be reversed, not just slowed.

Unity Biotechnology: The Senolytic Pioneer's Mixed Results

Senolytics—drugs that selectively eliminate senescent cells—have been among the most hyped longevity interventions of the past decade. Senescent cells accumulate with age, secreting inflammatory factors that damage surrounding tissue. In mice, clearing these cells extends lifespan and healthspan dramatically. Unity Biotechnology was founded to translate this to humans.

UBX0101: The Knee Trial That Failed

Unity's lead program, UBX0101, targeted senescent cells in the knee joint to treat osteoarthritis. The rationale was sound: osteoarthritis involves inflammation and tissue degradation driven partly by senescent cells. Local injection could eliminate these cells, reducing pain and potentially regenerating cartilage.

The Phase 2 trial enrolled 183 patients with moderate-to-severe painful knee osteoarthritis. Results were disappointing: UBX0101 showed no statistically significant difference from placebo in pain reduction. Unity announced it would not advance UBX0101 to pivotal studies, effectively ending the knee osteoarthritis program.

Lessons from Failure

The failure highlighted challenges in translating senolytic research to humans. Did UBX0101 fail to adequately clear senescent cells? Were senescent cells not the primary driver of osteoarthritis symptoms? Was the endpoint (pain reduction) too subjective or influenced by placebo effects? The trial couldn't definitively answer these questions.

As observers noted, "A single failed trial doesn't invalidate the entire senolytic approach—it shows the difficulty of getting dosing, delivery, and endpoints right in first-generation human studies."

UBX1325: Success in Eye Disease

Unity pivoted to ophthalmology with UBX1325, targeting senescent cells in diabetic macular edema (DME) and age-related macular degeneration. The eye offers advantages: it's easy to access for local injection, outcomes are objectively measurable (visual acuity), and the immune-privileged environment may enhance senolytic efficacy.

Results have been far more promising. Phase 1 data showed UBX1325 was safe and well-tolerated in advanced vascular eye disease. The Phase 2b ASPIRE trial in DME patients who had failed anti-VEGF treatment showed vision improvements: mean change of +5.2 ETDRS letters at 24 weeks and +5.5 letters at 36 weeks.

Crucially, UBX1325 demonstrated a favorable safety profile with no cases of serious ocular inflammation—a concern given the inflammatory nature of senescent cell clearance. The drug proved non-inferior to standard anti-VEGF therapy at most timepoints, suggesting it could become a viable treatment option.

The Senolytic Field Moves Forward

Unity's experience shows that senolytics work in humans—but success depends critically on selecting the right disease, delivery method, and endpoints. The eye may prove the ideal first indication, providing proof-of-concept that can then be extended to systemic applications. Other companies and academic groups continue exploring senolytics for kidney disease, lung fibrosis, and neurodegenerative conditions.

Young Blood: From Vampires to Venture Capital

Few longevity concepts capture public imagination like "young blood." The idea that factors in youthful blood could rejuvenate aged tissues has spawned biotech companies, questionable clinics, and serious scientific inquiry.

Alkahest and Plasma Fractions

Alkahest, cofounded in 2014 and later acquired by Spanish pharma giant Grifols for $146 million, pioneered therapeutic approaches using young fresh frozen plasma and plasma fractions enriched in albumin.

The company completed Phase 1 and 2 trials treating Alzheimer's and Parkinson's patients with young plasma fractions. Results showed the treatment was well-tolerated with promising preliminary effects, particularly in Alzheimer's patients. However, the company faces challenges in identifying optimal patient populations and securing funding for Phase 3 trials.

Alkahest is also developing a pill targeting an immune signaling molecule found in aged blood, showing early promise in age-related macular degeneration. This represents a shift from infusion therapy to more scalable small-molecule approaches.

Elevian and GDF11

Elevian, founded by researchers including Amy Wagers and Lee Rubin, focuses on GDF11 (Growth Differentiation Factor 11), a protein that declines with age and appears to promote vascular regeneration. The company is developing a recombinant GDF11 drug intended to revascularize damaged brain tissue after stroke.

Recent research evaluated recombinant GDF11 in rat stroke models, showing therapeutic benefits. However, Elevian remains "still a couple years away from testing its lab-grown version of GDF11 in human trials" as of current reports.

The Cautionary Tale

The "young blood" field has been marred by premature commercialization. In 2019, the FDA took action against clinics offering unproven "young blood" transfusions to healthy aging individuals, warning of safety concerns and lack of efficacy evidence.

The legitimate research continues, but it's focused on identifying specific factors in young blood (or inhibitory factors in old blood) rather than crude plasma transfusions. The future likely involves targeted molecules like GDF11, rather than wholesale blood exchange.

NAD+ Precursors: Cellular Energy in a Pill

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme essential for cellular energy metabolism, DNA repair, and activation of sirtuins—proteins linked to longevity. NAD+ levels decline with age, and precursors that boost NAD+ (nicotinamide riboside [NR] and nicotinamide mononucleotide [NMN]) have become among the most popular longevity supplements.

ChromaDex and Nicotinamide Riboside

ChromaDex, the company behind the NR supplement Tru Niagen, has sponsored several human trials. A recent double-blind, placebo-controlled trial evaluated NR (2000 mg/day) in long-COVID patients, finding improvements in NAD+ levels and cognitive symptoms.

Another study randomized 20 older adults with mild cognitive impairment to receive 1g daily NR or placebo over 10 weeks, showing modest benefits on cognitive measures. A pilot study comparing routes of administration found that intravenous NR and NAD+ boosted blood NAD+ levels, though oral NR was less effective.

NMN Human Studies

NMN, another NAD+ precursor, has garnered attention following studies in mice showing dramatic anti-aging effects. Multiple human trials have now been completed, though most were small pilot studies.

A systematic review and meta-analysis of nine studies including 412 participants found NMN significantly increased muscle mass and improved liver enzyme levels (ALT). A February 2025 study in healthy men found liposomal NMN significantly increased NAD+ compared to non-liposomal formulations, with levels remaining elevated four weeks after cessation.

The Verdict on NAD+ Precursors

As a comprehensive research review concluded, NAD+ boosters show promise for specific applications—cognitive function, metabolic health, exercise recovery—but evidence for broad anti-aging effects in healthy humans remains limited. Most trials have been short-term (weeks to months) with surrogate endpoints. Longer studies measuring functional outcomes and biological age markers are needed.

The clinical evidence suggests NAD+ precursors are safe and can elevate NAD+ levels, but whether this translates to meaningful healthspan or lifespan extension in humans remains an open question.

Senolytics in Humans: Beyond Unity

While Unity Biotechnology pursued proprietary senolytic compounds, academic researchers have tested existing drug combinations, particularly dasatinib plus quercetin (D+Q) and fisetin.

Dasatinib + Quercetin Trials

D+Q combines a cancer drug (dasatinib) with a plant flavonoid (quercetin). In mice, this combination selectively eliminates senescent cells and extends healthspan. Human trials have explored D+Q in idiopathic pulmonary fibrosis, kidney disease, and cognitive decline.

A Phase 1 trial in pulmonary fibrosis showed D+Q was feasible and tolerable, though efficacy endpoints weren't met. A pilot study in older adults at risk for Alzheimer's (published February 2025) gave participants 100mg dasatinib and 1250mg quercetin for two days every two weeks over 12 weeks. The study assessed feasibility, safety, and preliminary cognitive effects.

A protocol for a larger trial in mental disorders aims to test whether D+Q can mitigate age-related health and cognitive decline in older adults with schizophrenia, schizoaffective disorder, and treatment-resistant depression.

Epigenetic Clock Effects: Unexpected Results

A fascinating longitudinal study examined effects of D+Q and fisetin on DNA methylation clocks. Surprisingly, 19 participants receiving D+Q for six months showed increases in epigenetic age acceleration on first-generation clocks and mitotic clocks, along with decreased telomere length. However, second and third-generation clocks showed no significant changes.

This paradoxical finding highlights the complexity of interpreting aging biomarkers. Did senolytics accelerate aging, or do changes in epigenetic clocks reflect increased cellular turnover (a potentially beneficial process)? The study underscores that we don't yet fully understand what epigenetic age changes mean in the context of interventions.

The AFFIRM Study with Fisetin

The Alleviation by Fisetin of Frailty, Inflammation, and Related Measures (AFFIRM) study is exploring fisetin's effects on musculoskeletal aging and frailty. Fisetin, a flavonoid found in strawberries and other fruits, has shown senolytic properties in preclinical studies.

Results are pending, but the trial represents an important test of whether dietary compounds with senolytic activity can meaningfully impact age-related frailty—a highly clinically relevant endpoint.

Epigenetic Reprogramming: The Ultimate Reset?

Perhaps no longevity approach has generated more excitement—and capital—than epigenetic reprogramming. The idea is radical: could we reset aged cells to a younger state by altering their epigenetic marks, the chemical modifications that control gene expression?

The Science of Yamanaka Factors

In 2006, Shinya Yamanaka discovered that four transcription factors (Oct4, Sox2, Klf4, c-Myc—collectively "Yamanaka factors") could reprogram adult cells into induced pluripotent stem cells (iPSCs), essentially resetting them to an embryonic state. This won him the Nobel Prize.

But full reprogramming to pluripotency isn't useful for anti-aging—you don't want neurons becoming stem cells. The breakthrough was partial reprogramming: brief, controlled exposure to Yamanaka factors that resets some epigenetic marks without dedifferentiating cells. In mice, this approach has reversed aspects of aging, restored function to damaged tissues, and even extended lifespan.

Altos Labs: The $3 Billion Moonshot

Altos Labs launched in 2022 with approximately $3 billion in funding—likely the largest startup capital raise in biotech history. The company assembled a scientific dream team including Yamanaka himself and Juan Carlos Izpisúa Belmonte, who pioneered partial reprogramming approaches.

Altos focuses on "cellular rejuvenation technology" aimed at reversing disease and age-related decline. The company's recent presentations target "mesenchymal drift"—the tendency of aged cells to lose specialized identity and acquire inflammatory properties.

However, as of 2024-2025, Altos has yet to name specific clinical candidates or announce trial timelines. The appointment of Dr. Joan Mannick as Chief Medical Officer signals movement toward clinical development, but "much of Altos' science is currently built on preclinical findings."

Turn Bio: Targeting Skin First

Turn Bio, another epigenetic reprogramming company, has taken a more focused approach: skin rejuvenation as the first indication. In March 2025, Turn Bio acquired ARMMs vesicular technology to enhance delivery of reprogramming therapies.

More significantly, in 2026, the company plans to initiate clinical trials for its skin rejuvenation therapy—potentially one of the first epigenetic reprogramming approaches to reach human testing. Skin offers advantages similar to the eye: accessible, observable, measurable outcomes, and a clear cosmetic/medical market.

Life Biosciences and ER-100

Life Biosciences, another player in this space, expects to advance ER-100 into clinical development by early 2026, which would be "one of the first applications of cellular rejuvenation through partial epigenetic reprogramming in humans."

The Challenge Ahead

Epigenetic reprogramming faces significant hurdles. Delivery is challenging—how do you safely deliver reprogramming factors to specific tissues or systemically? Safety is paramount—inappropriate reprogramming could trigger cancer or tissue dysfunction. And endpoints are unclear—what constitutes successful partial reprogramming in a living human?

The field is at a critical juncture: transitioning from spectacular animal studies to the messy reality of human trials. The next few years will reveal whether epigenetic reprogramming can deliver on its extraordinary promise.

Biological Age Clocks as Trial Endpoints

A major challenge for longevity trials has been measuring success. Waiting decades for mortality data isn't feasible for most studies. This has driven intense interest in biological age clocks—algorithms that estimate how fast someone is aging based on measurable biomarkers.

Generations of Clocks

Epigenetic clocks use DNA methylation patterns to predict chronological age, mortality risk, and healthspan. First-generation clocks like Horvath's and Hannum's focused on predicting chronological age. Second-generation clocks like PhenoAge and GrimAge predict time-to-death and disease risk. Third-generation clocks like DunedinPACE measure the pace of biological aging.

An unbiased comparison of 14 epigenetic clocks found that second and third-generation clocks significantly outperform first-generation ones for predicting incident diseases, validating their use as clinical endpoints.

Using Clocks in Trials

The Clock Foundation advocates for standardizing epigenetic clock use in clinical trials, arguing that "epigenetic age is the most accurate measure of biological age and age-related disease risk available today, which justifies the use of epigenetic clocks to estimate the effectiveness of putative aging interventions."

TRIIM-X and other recent trials are using epigenetic clocks as primary or secondary endpoints. This allows trials to demonstrate biological age changes in months or years rather than waiting decades for clinical outcomes.

Recommendations for the Field

A 2025 paper in npj Aging provided recommendations for biomarker data collection in longevity trials. Key points include:

The Validation Challenge

As a critical review noted, moving epigenetic clocks from population science to clinical use requires careful validation. Clocks must demonstrate that changes predict meaningful health outcomes, not just correlate with them. A provocative paper asked, "Do we actually need aging clocks?"—questioning whether clocks add value beyond measuring established biomarkers like blood pressure, glucose, and lipids.

The answer likely depends on the application. For trials testing broad anti-aging interventions, clocks may capture effects missed by conventional biomarkers. For interventions targeting specific diseases, established clinical endpoints may be more appropriate.

The Regulatory Landscape: Can We Treat Aging?

The most fundamental obstacle to longevity medicine remains regulatory: aging is not an approved indication. This creates perverse incentives and slows progress.

The Current State

As a scoping review of regulatory environments found, researchers "did not find any regulatory frameworks by government agencies, such as the FDA or the EMA, for gerotherapeutics." This forces companies to target specific age-related diseases rather than aging itself.

However, the NIA has provided guidance on FDA review of geroscience-related IND applications, emphasizing the importance of early FDA dialogue. As the guidance notes, "sponsors' dialog with FDA and understanding of FDA perspectives on the specific features of their potential drug development program are likely to be crucial."

TAME as a Precedent

TAME's FDA approval for its composite endpoint design represents progress. As analysts have noted, "TAME holds the potential to be the first study that could lead to considering aging, or at least multimorbidity, as a therapeutic indication."

The trial's composite endpoint—time to cardiovascular events, cancer, cognitive decline, or death—represents a pragmatic compromise. It measures clinically meaningful outcomes without explicitly claiming to treat "aging." A framework for translational geroscience suggests this incremental approach may be the only feasible path forward.

The Repurposing Pathway

A proposed process for repurposing FDA-approved drugs to target aging offers another route. By selecting drugs with known safety profiles and evidence of geroprotective effects, researchers can bypass early-phase trials and move directly to efficacy testing.

Metformin, rapamycin, and other candidates for repurposing have decades of human safety data. This dramatically reduces development risk and cost, making trials more attractive to funders—though it also eliminates profit potential for pharmaceutical companies.

The Need for FDA Leadership

As advocates argue, "Anti-aging drugs need FDA support and increased clinical trial participation by older adults." Until the FDA creates a clear pathway for gerotherapeutics—whether by recognizing aging as an indication or establishing alternative approval criteria—progress will remain slow.

The creation of ARPA-H, which is now supporting TAME, suggests government recognition that aging research deserves dedicated funding pathways outside traditional NIH mechanisms. This could accelerate the field significantly.

Challenges in Longevity Trials

Beyond regulatory hurdles, longevity trials face unique operational challenges that complicate their execution.

Recruitment and Retention

Clinical trials targeting aging struggle with recruitment for several reasons. Healthy older adults may not see themselves as needing intervention. Trials requiring lifestyle changes (like CALERIE's caloric restriction) face high dropout rates. Long trial durations test participants' commitment.

Decentralized trial models like PEARL and TRIAD may help by reducing participant burden—no frequent clinic visits, testing done at home or by local providers, digital monitoring tools. But these introduce their own challenges in data quality and protocol adherence.

Biomarker Validation

As a comprehensive review on biomarker validation noted, "progress requires establishing a clear association between biomarkers and meaningful health outcomes through well-powered, prospective clinical studies rather than relying solely on correlative or surrogate endpoint data."

Many aging biomarkers are correlated with outcomes in observational studies but haven't been validated as trial endpoints. Does improving biomarker X actually lead to better health outcomes, or is it just an epiphenomenon? Only prospective trials can answer this.

Placebo Effects and Blinding

Many longevity interventions produce noticeable effects—weight loss, energy changes, side effects—that compromise blinding. Participants may correctly guess their treatment assignment, introducing bias. Subjective endpoints like pain, well-being, and cognitive function are particularly vulnerable to placebo effects.

This argues for using objective biomarkers (epigenetic age, inflammatory markers, physical performance tests) alongside subjective measures, and for careful attention to blinding procedures.

Heterogeneity of Aging

Aging varies enormously between individuals. Genetic background, lifestyle, medical history, and environmental exposures all influence how someone ages. This heterogeneity makes it difficult to demonstrate consistent intervention effects across populations.

One solution is basket trials that enroll participants based on biomarker profiles rather than chronological age. For example, a trial might select participants with elevated biological age, inflammatory markers above a threshold, or evidence of specific aging mechanisms (like cellular senescence burden). This increases the likelihood that the intervention will produce measurable effects.

Compliance Challenges

As CALERIE demonstrated, achieving and maintaining intervention targets in free-living humans is difficult. Participants achieved only 12% caloric restriction when 25% was targeted. Rapamycin dosing requires careful monitoring for side effects and drug interactions. Supplement trials face questions about absorption and bioavailability.

Digital tools—smartphone apps, wearable sensors, telemedicine check-ins—can improve compliance monitoring and support, but add complexity and cost to trial operations.

The Future: Innovative Trial Designs

The longevity field is beginning to adopt trial designs that address some of these challenges.

Adaptive Trials

Adaptive trial designs allow protocol modifications based on interim data analyses. If a dose appears ineffective or unsafe, it can be adjusted mid-trial. If biomarkers suggest one subpopulation responds better, enrollment can be enriched for that group. This makes trials more efficient and ethical.

Regulatory bodies like the FDA and EMA have increasingly endorsed adaptive designs, particularly for innovative therapies. For longevity trials with long durations, the ability to course-correct based on emerging data is invaluable.

AI-Optimized Protocols

AI is transforming clinical trials by enabling real-time protocol optimization. Machine learning algorithms can analyze incoming data to identify which participants are responding, predict dropout risk, and recommend protocol adjustments.

The AI-based clinical trials market grew from $7.73 billion in 2024 to $9.17 billion in 2025, with projections reaching $21.79 billion by 2030. This represents a fundamental shift from static protocols to dynamic, adaptive frameworks.

For longevity trials, AI could personalize interventions based on individual biomarker responses, predict which participants are most likely to benefit, and identify novel biomarker combinations that improve outcome prediction.

Decentralized and Hybrid Models

Decentralized clinical trials (DCTs) have become mainstream in 2025, allowing sponsors to reduce logistical barriers, improve patient engagement, and recruit from diverse geographic and demographic populations.

For aging research, DCTs are particularly valuable. They enable participation by individuals who might not be near academic medical centers. They reduce the burden of frequent clinic visits that can discourage enrollment. And they generate real-world data on how interventions perform in typical living conditions rather than the artificial environment of a clinical research center.

Basket and Platform Trials

Basket trials enroll participants based on shared characteristics (like biomarker profiles) rather than single diseases. Platform trials test multiple interventions using a shared control group and infrastructure.

For longevity research, these designs are ideal. A platform trial could simultaneously test metformin, rapamycin, NAD+ precursors, and senolytics, comparing them head-to-head and in combination. Participants could be stratified by biological age, inflammation levels, or senescent cell burden. This would generate comparative effectiveness data much faster than separate trials for each intervention.

The Longevity Clinic Model

As longevity clinics proliferate, they create opportunities and challenges. These clinics treat thousands of patients with various interventions, generating real-world data at scale. However, as critics note, "many clinics lack standardized protocols, and the tools they use, such as biological age calculators or hormone therapies, often lack accuracy or clear clinical value."

If longevity clinics could be organized into practice-based research networks with standardized data collection, they could function as massive observational studies or pragmatic trial platforms. This would require significant coordination and quality control, but the potential for accelerating knowledge is substantial.

Where We Stand in 2026

The longevity clinical trial landscape has transformed over the past five years. We've moved from speculation about whether aging can be targeted to serious trials testing specific interventions in humans.

What we've learned:

What remains unknown:

The challenges ahead:

Conclusion: A New Chapter in Human Health

For the first time in human history, we are testing whether aging itself can be slowed, stopped, or reversed. The trials described in this article represent the first wave of this effort—imperfect, incomplete, but profoundly important.

Some will fail. TAME may find metformin ineffective. Epigenetic reprogramming might prove too difficult to control safely. Individual senolytics might not work as standalone therapies. But each failure teaches us something about the biology of aging and the challenges of intervening in it.

Others will succeed, at least partially. We'll identify interventions that reliably improve healthspan biomarkers, delay onset of age-related diseases, or extend functional lifespan. These will become the foundation for next-generation trials testing combinations, optimized dosing, and personalized approaches.

The pace of progress is accelerating. As 2025 demonstrated, we're seeing more human trials, better biomarkers, innovative trial designs, and growing investment. As recent analyses show, the field is shifting from preclinical proof-of-concept to focused clinical evaluation.

The next decade will be critical. If TAME succeeds, it opens the regulatory pathway for a generation of aging interventions. If TRIAD shows rapamycin extends healthy lifespan in dogs, human trials will follow. If Turn Bio or Life Biosciences demonstrate safe, effective epigenetic reprogramming in humans, it could transform medicine.

We stand at the threshold of a new era in medicine—one where aging is not an immutable fate but a modifiable process. The clinical trials underway today are writing the first chapter of that story. Whether it ends in triumph or disappointment, we are learning. And in science, learning is always progress.

Related Reading

Metformin and Longevity · Rapamycin: The mTOR Inhibitor · Senolytic Therapy · Caloric Restriction · Biological Age Measurement · Epigenetic Clocks · NAD+ Precursors · Epigenetic Reprogramming · Key Researchers · Longevity Biotech Companies · Blood Biomarkers of Aging · Hallmarks of Aging · Exercise and Longevity · Model Organisms in Aging Research · History of Aging Research